Should Alecensa (Alectinib) be the new first line ALK inhibitor for ALK-positive NSCLC?

Article

Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of patients with non-small cell lung cancer (NSCLC) who have the molecular driver known as an anaplastic lymphoma kinase (ALK) rearrangement, which we now routinely test for from the tumor tissue of patients with a non-squamous metastatic NSCLC.

Clinical Trial Spotlight: Should a Second Generation ALK Inhibitor be First Line Therapy for Patients with ALK-Positive NSCLC?

Article

Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.

Subscribe to ALK inhibitor